Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183: A Novel, Highly Potent, Selective PDE4 Inhibitor in Patients with Plaque Psoriasis at EADV Congress 2023
Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183: A Novel, Highly Potent, Selective PDE4 Inhibitor in Patients with Plaque Psoriasis at EADV Congress 2023 Description TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that positive findings from the phase II clinical trial of…